Pharmaceuticals signs a cooperation agreement with CanSino Bio to supply, manufacture, and market the MCV4 vaccine.

SPIMACO

SPIMACO

2070.SA

0.00

Riyadh - Mubasher: The Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) announced signing a cooperation agreement with CanSino Biologics (CanSino Bio) to supply, manufacture, and market the MCV4 meningococcal vaccine in Saudi Arabia and selected markets in the Middle East and North Africa (MENA) region.

The company explained in a statement on the Saudi Stock Exchange (Tadawul) today, Wednesday, that the agreement, signed on March 25, 2025, grants SPIMACO exclusive rights to supply, manufacture, distribute, and market the vaccine in target markets. This is part of its strategy to strengthen its presence in the vital vaccines sector and support health security in the region.

SPIMACO indicated that the expected revenues from this agreement during the fifth year after launch represent approximately 4% of the company's total revenues for 2023, and the contract term extends to five years.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.